Re: "Botulinum toxin type A as a migraine preventive treatment" (Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX Migraine Clinical Research Group. Headache. 2000;40:445-450).
Galvez-Jimenez
N
N
Hanson
M R
MR
D001763:Blepharoptosis / Q000139:chemically induced*; D019274:Botulinum Toxins, Type A / Q000009:adverse effects* / Q000627:therapeutic use; D004172:Diplopia / Q000139:chemically induced*; D005152:Facial Muscles / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular / Q000379:methods; D008881:Migraine Disorders / Q000517:prevention & control*; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000627:therapeutic use
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A